You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC

Diagnostic Strategies in Advanced NSCLC: Guiding Treatment Decisions Through Pathology

  • Authors: H. Jack West, MD; Christina Lockwood, PhD, DABCC, DABMGG; Laura J. Tafe, MD; Heather Wakelee, MD
  • CME / ABIM MOC Released: 12/21/2017
  • THIS ACTIVITY HAS EXPIRED FOR CREDIT
  • Valid for credit through: 12/21/2018, 11:59 PM EST
Start Activity


Target Audience and Goal Statement

This activity is intended for pathologists, oncologists, pulmonologists, and radiologists.

The goals of this activity are to help guide treatment selection in patients with advanced non-small cell lung cancer (NSCLC) by closing the gap related to the use of biomarker testing and to improve physician knowledge and understanding, which can contribute to improved quality of patient care.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Clinical trial data supporting the use of biomarkers to guide treatment selection in patients with advanced NSCLC
  • Have greater competence related to
    • Selecting the most appropriate testing strategy for detection of mutations or protein expression to allow accurate characterization of a patient's NSCLC
    • Accurate reporting of biomarker test results to other members of the care team to help guide optimal treatment selection throughout the continuum of a patient's disease


Disclosures

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.


Moderator

  • H. Jack West, MD

    Medical Oncology Medical Director, Thoracic Oncology Program, Swedish Cancer Institute, Seattle, Washington

    Disclosures

    Disclosure: H. Jack West, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: ARIAD Pharmaceuticals, Inc.; AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Genentech, Inc.; Merck & Co., Inc.; Roche; Takeda Pharmaceuticals North America, Inc.
    Served as a speaker or a member of a speakers bureau for: ARIAD Pharmaceuticals, Inc.

    Dr West does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Dr West does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Panelists

  • Laura J. Tafe, MD

    Associate Professor, Dartmouth-Hitchcock Medical Center and the Geisel School of Medicine at Dartmouth; Assistant Director, Laboratory for Clinical Genomics and Advanced Technologies, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire

    Disclosures

    Disclosure: Laura J. Tafe, MD, has disclosed no relevant financial relationships.

    Dr Tafe does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Dr Tafe does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

  • Christina Lockwood, PhD, DABCC, DABMGG

    Associate Professor, Department of Laboratory Medicine; Director, Genetics and Solid Tumors Laboratory, University of Washington, Seattle, Washington

    Disclosures

    Disclosure: Christina Lockwood, PhD, DABCC, DABMGG, has disclosed no relevant financial relationships.

    Ms Lockwood does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Ms Lockwood does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

  • Heather Wakelee, MD

    Professor of Medicine, Oncology, Stanford University, Stanford Cancer Institute, Stanford, California

    Disclosures

    Disclosure: Heather Wakelee, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: ACEA Biosciences, Inc.; Genentech, Inc.; Helsinn Therapeutics, Inc; Peregrine Pharmaceuticals Inc.; Pfizer Inc.
    Received grants for clinical research from: AstraZeneca Pharmaceuticals LP/MedImmune Inc; Bristol-Myers Squibb Company; Celgene Corporation; Clovis Oncology; Exelixis, Inc.; Genentech, Inc./Roche; Gilead Sciences, Inc.; Lilly;.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Pharmacyclics, Inc.; Xcovery Vision

    Dr Wakelee does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Dr Wakelee does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Editor

  • Davecia R. Cameron, MS

    Scientific Director, Medscape, LLC

    Disclosures

    Disclosure: Davecia R. Cameron, MS, has disclosed no relevant financial relationships.

CME/Content Reviewer

  • Nafeez Zawahir, MD

    CME Clinical Director, Medscape, LLC

    Disclosures

    Disclosure: Nafeez Zawahir, MD, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.


Accreditation Statements

Medscape

Interprofessional Continuing Education

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Medscape, LLC staff have disclosed that they have no relevant financial relationships.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC

Diagnostic Strategies in Advanced NSCLC: Guiding Treatment Decisions Through Pathology

Authors: H. Jack West, MD; Christina Lockwood, PhD, DABCC, DABMGG; Laura J. Tafe, MD; Heather Wakelee, MDFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME / ABIM MOC Released: 12/21/2017

Valid for credit through: 12/21/2018, 11:59 PM EST

processing....

Q&A

Educational Impact Challenge

The goals of this activity are to help guide treatment selection in patients with advanced NSCLC by closing the gap related to the use of biomarker testing and to improve physician knowledge and understanding, which can contribute to improved quality of patient care.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

  • Print